Arteris achieved a record annual contract value plus royalties of $65.1 million in Q4 2024, driven by increased adoption of AI-driven enterprise computing and automotive SoCs. CEO Charlie Janac ...

Plus Therapeutics plans to conduct an FDA end-of-Phase 1 meeting to define the approval pathway for REYOBIQ for LM resulting from breast cancer. The meeting will focus on endpoints, comparators ...